• Corpus ID: 33069208

Treating Dementia with Vitamin B 3 and NADH

  title={Treating Dementia with Vitamin B 3 and NADH},
  author={Jonathan E. Prousky},
Dementia affects approximately 5 million people in the United States, and about 475,000 elderly Canadians. Dementia is a debilitating and often progressive illness. The most common type of dementia is Alzheimer’s disease, followed by vascular types. There is a need to investigate novel treatments because the current crop of medications have limited value. Niacin might be a worthwhile treatment to consider. Research has shown that the risks of incident AD increase when patients have insufficient… 

Tables from this paper

Nicotinic acid and derivatives as multifunctional pharmacophores for medical applications
Cardiovascular disease is one of the major health problems worldwide. It is a vascular condition known as an atherosclerosis referring to the accumulation of immune cells and lipids in vascular walls


Statins and dementia
  • L. Kuller
  • Medicine
    Current atherosclerosis reports
  • 2007
In spite of negative studies, the possibility remains that statin therapy may reduce risk of dementia and AD and the results of two secondary prevention trials will be reported shortly.
ENADA/NADH improves cognitive impairment of Alzheimer patients
ENADAINADH is a safe medication that improves cognitive impairment in patients with AD and several subjects also shown clinical improvement in cognitive functioning.
Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline
Dietary niacin may protect against Alzheimer’s disease and age related cognitive decline and stronger associations were observed in analyses that excluded participants with a history of cardiovascular disease.
Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.
The present findings support NADH as a treatment for AD with no differences between groups in measures of attention, memory, or in clinician ratings of dementia severity.
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before
The discovery of new drugs efficacious in AD subjects is an ambitious goal, however, and one that will require close, active collaboration by pharmacologists, chemists and clinicians.
Plasma cholesterol and risk for late-onset Alzheimer’s disease
It is shown that higher levels of high-density lipoprotein cholesterol, total cholesterol and non-high-density cholesterol are associated with lower risk of AD, and the need for understanding the molecular mechanisms behind this association is discussed.
Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.
  • J. Birkmayer
  • Medicine
    Annals of clinical and laboratory science
  • 1996
The Coenzyme nicotinamide adenine dinucleotide (NADH) has been used as medication in 17 patients suffering from dementia of the Alzheimer type in an open label trial. In all patients evaluated so
Tryptophan and nutritional status of patients with senile dementia.
The nutritional status of severely demented patients was compared with that of similarly aged controls in the community and an earlier finding in patients with senile dementia of reduced fasting plasma concentrations of tryptophan was confirmed for total and protein bound fractions.
No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia
It is concluded that NADH is unlikely to achieve cognitive improvements in an extent reported earlier, and theoretical arguments against an effectiveness of this compound in dementia disorders are presented.
Pilot study of amino acids in senile dementia.
It is found that the †̃¿ low absorbers' improved in both intestinal and mental function following a high protein diet.